IP Library › Granted Patent US 9,034,839
Granted Patent B2
US 9,034,839 · App. 13/826,775 · Granted May 19, 2015

miRNA modulators of thermogenesis

Inventor: Marc Thibonnier (Naples, FL)
Assignee: Aptamir Therapeutics, Inc.
C12N15/113C12Q1/68C12N2310/141C12N2310/16C12N2310/3519C12N2320/11C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,034,839
App. No.
13/826,775
Granted
May 19, 2015
Kind
B2
Abstract

Provided are novel methods and compositions for the modulation of thermogenesis. Such methods are particularly advantageous in that they allow for the reduction of body fat in a subject without the subject having to adjust their caloric intake through dieting, modify their physical activity or undergo bariatric surgery. Accordingly, the methods of the invention are particularly useful for treating or preventing obesity. Also provided are methods of screening for novel agents that modulate the activity of thermogenic regulators.

Claims (12)

1. A method of modulating respiratory chain uncoupling in a cell or thermogenesis in a tissue, the method comprising contacting the cell or tissue with a miRNA agent that increases activity of at least one mitochondrial uncoupler selected from UCP1 or UCP2; wherein the miRNA agent is hsa-miR-515-3p or an agomir thereof.

2. The method of claim 1 , wherein the cell is a pre-adipocyte, adipocyte, adipose tissue derived mesenchymal stem cell, hepatocyte, myocyte, or a precursor thereof.

3. The method of claim 1 , wherein the tissue is brown fat, white fat, subcutaneous adipose tissue, liver or muscle.

4. The method of claim 3 , wherein the tissue is contacted with the miRNA agent ex vivo.

5. The method of claim 1 , wherein the mitochondrial uncoupler is UCP1 or UCP2.

6. The method of claim 1 , wherein the miRNA agent is linked to targeting moiety.

7. The method of claim 6 , wherein the targeting moiety is an aptamer.

8. The method of claim 6 , wherein the targeting moiety delivers the miRNA agent to a specific cell type or tissue.

9. The method of claim 1 , wherein the miRNA agent directly binds to the mRNA, 3′UTR, 5′UTR, coding, or promoter regions of UCP1 or UCP2.

10. The method of claim 1 , wherein the miRNA agent modulates the activity of an activator or repressor of a mitochondrial uncoupling protein.

11. The method of claim 10 , wherein the miRNA agent directly binds to the mRNA, 3′UTR, 5′UTR, coding, or promoter regions of the activator or repressor.

12. The method of claim 1 , wherein the agent is an agomir of hsa-miR-515-3p.

Assignments (2)
CHANGE OF ADDRESS Recorded May 18, 2015
From: APTAMIR THERAPEUTICS, INC.
To: APTAMIR THERAPEUTICS, INC.
Reel/Frame 035706/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2013
From: THIBONNIER, MARC
To: APTAMIR THERAPEUTICS, INC.
Reel/Frame 030126/0845 →
Continuity (3)
Provisional Application 61681750 · Aug 10, 2012
Provisional Application 61636059 · Apr 20, 2012
Related Publication 20130331433A1 · Dec 12, 2013